Nektar Therapeutics (NKTR) Has Jumped To A New High On Study Results

Leslie Hanson
November 13, 2017

This represents an increase of Infinity compared to the typical volume of 0 put options. Also, SVP Stephen K. Doberstein sold 396,323 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, November 8th.

Reading levels close to +100 point to potential overbought range while a reading close to -100 would indicate possible oversold territory. Following the completion of the sale, the chief executive officer now directly owns 152,504 shares in the company, valued at $2,937,227.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Stephen K. Doberstein, Sr VP let go of $10,680,905 worth of shares at a price of $26.95 on Wednesday the 8th. The shares were sold at an average price of $19.32, for a total transaction of $32,863.32. Rothschild Asset Management Inc. now owns 1,182,422 shares of the biopharmaceutical company's stock valued at $28,378,000 after purchasing an additional 56,672 shares during the last quarter. The disclosure for this purchase can be found here. Insiders have sold a total of 1,024,757 shares of company stock valued at $25,974,361 in the last ninety days.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. While in the same Quarter Previous year, the Actual EPS was $-0.28. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company's stock valued at $110,000 after acquiring an additional 692 shares during the last quarter. Genesee Valley Trust Co. boosted its stake in shares of Nektar Therapeutics by 0.4% in the third quarter. Municipal Employees Retirement System of MI now owns 30,250 shares of the biopharmaceutical company's stock valued at $520,000 after buying an additional 490 shares during the last quarter. Arizona State Retirement System boosted its position in shares of Nektar Therapeutics by 1.0% during the second quarter. Piedmont Investment Advisors LLC now owns 33,545 shares of the biopharmaceutical company's stock valued at $656,000 after buying an additional 24,344 shares during the last quarter. LS Investment Advisors LLC boosted its stake in Nektar Therapeutics by 8.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 952,443 shares of the biopharmaceutical company's stock valued at $18,620,000 after buying an additional 79,510 shares during the last quarter. Finally, Evercore ISI began coverage on Nektar Therapeutics in a report on Thursday, August 17th. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company's stock worth $154,000 after buying an additional 3,392 shares during the period. Corporate insiders own 6.10% of the company's stock.

Based on current stock levels, Nektar Therapeutics shares are trading 16.65% off of the 50-day high and 90.35% away from the 50-day low.

Based on Nektar Therapeutics' latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $153 million and quarterly net profit of $60.87 million.

The company reported its EPS on 9/29/2017.

"In the dose-escalation stage of the PIVOT trial, we've observed important response rates across all three tumor types - melanoma, renal cell carcinoma and non-small lung cancer - in both PD-L1 positive and PD-L1 negative patients", said Mary Tagliaferri, M.D., Senior Vice President of Clinical Development at Nektar Therapeutics. After having $0.37 EPS previously, Nektar Therapeutics's analysts see -191.89 % EPS growth. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. On November 8 Jefferies Group LLC held the company rating at "Buy" targeting a price of $35.00. As a company has 155.35M shares outstanding and its current share price is $32.50, the market cap is $5.05B. On Monday, May 15 CHESS ROBERT sold $98,950 worth of Nektar Therapeutics (NASDAQ:NKTR) or 5,000 shares. They issued an "outperform" rating for the company. BidaskClub lowered shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, August 11th. If the $41.31 price target is reached, the company will be worth $537.30 million more.

Analysts have given a mean recommendation of 2.90 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Currently, the stock has a 1 Year Price Target of $29.55.

WARNING: "Nektar Therapeutics Target of Unusually Large Options Trading (NKTR)" was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another site, it was illegally copied and reposted in violation of US and worldwide copyright laws.

Other reports by Iphone Fresh

Discuss This Article